Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome - Slideshow
Neurogene Reveals Proposed Public Offering; No Size Disclosed
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett Syndrome
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene To Highlight ICV As Routine Neurosurgical Procedure Providing Broad Biodistribution Of Gene Therapy To Brain And Nervous System At ASGCT Meeting
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180
Neurogene shares are trading higher. The company, on Tuesday, reported Q4 financial results.
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
